ACM
IKT icon

ADAR1 Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

ADAR1 Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
7,387,205
+780,633
+12% +$1.4M 0.69% 34
2026
Q1 		$11.1M Sell
6,606,572
-1,457,377
-18% -$2.59M 0.65% 41
2025
Q4 		$16.5M Buy
8,063,949
+2,816,346
+54% +$4.48M 1.21% 16
2025
Q3 		$8.5M Buy
5,247,603
+125,498
+2% +$217K 0.8% 30
2025
Q2 		$9.99M Hold
5,122,105
– – 1.53% 14
2025
Q1 		$11.2M Buy
5,122,105
+19,100
+0.4% +$48K 2.08% 11
2024
Q4 		$16.6M Buy
+5,103,005
New +$12.7M 3.31% 8

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ADAR1 Capital Management's IKT Position: Q2 2026 in Review

ADAR1 Capital Management increased its Inhibikase Therapeutics (IKT) stake by 12% in Q2 2026, buying an estimated $1.4M and bringing the position to 7,387,205 shares worth $15M. The position accounts for 0.69% of the portfolio, ranked #34.

ADAR1 Capital Management first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.6M in Q4 2024. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • ADAR1 Capital Management held 7,387,205 shares of Inhibikase Therapeutics worth $15M as of Q2 2026.
  • ADAR1 Capital Management bought 780,633 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Inhibikase Therapeutics made up 0.69% of ADAR1 Capital Management's portfolio in Q2 2026, its #34 holding.
  • ADAR1 Capital Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • ADAR1 Capital Management's Inhibikase Therapeutics position peaked at $16.6M in Q4 2024.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.